Monopar Therapeutics Inc. Quarterly report pursuant to Section 13 or 15(d)

Note 7 - Loss per Share

3 Months Ended

Mar. 31, 2024

Note 7 - Net Loss Per Share

Basic and diluted net loss per common share was calculated as follows:

	Three Months Ended March 31,
(in thousands, except for net loss per share)	2024			2023
Numerator:
Net loss	$	(1,641	)	$	(2,435	)

Denominator:
Weighted-average common shares outstanding, basic and diluted		15,980			13,106

Net loss per common share, basic and diluted	$	(0.10	)	$	(0.19	)

Anti-dilutive potential common stock equivalents excluded from the calculation of net loss per share
Stock options to purchase common stock		2,119			2,146
Unvested restricted stock units		367			600